# Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The HERNATA Study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/phase-iii-randomized-study-comparing-docetaxel-plus-trastuzumab-with-vinorelbine/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Michael Andersson,Elisabeth Lidbrink,Karsten Bjerre,Erik Wist,Kristin Enevoldsen,Anders Bonde Jensen,Per Karlsson,Ulla Brix Tange,Peter G. Sørensen,Susanne Möller,Jonas Bergh,Sven Tyge Langkjer |
| Citations | 295 |
| DOI | 10.1200/jco.2010.30.8213 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2127457632 |
| PMID | 21149659 |
| Type | article |
| Year | 2010 |

## Paper authors

- [Anders Bonde Jensen](https://scholariq.org/researchers/anders-bonde-jensen/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Paper topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.